Organisation paid for research Program year 2022 Source: CMS Open Payments

Quality Medical Research

Neither a doctor nor a teaching hospital

Research payments

$609,662

77 payments

Through program year 2022, Quality Medical Research is reported as receiving $609,662 in research payments, across 77 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $6,601 1
2021 Research $32,773 18
2020 Research $451,026 30
2019 Research $119,262 28

Breakdown

Who paid Research payments · program years 2019–2022
  1. Ironwood Pharmaceuticals, Inc $437,072 11 payments
  2. Allergan Inc. $164,697 62 payments
  3. Celgene Corporation $7,756 1 payment
  4. E.R. Squibb & Sons, L.L.C. $137 3 payments
Studies the money was for Research payments · program years 2019–2022
  1. C3718-302 $437,072 11 payments
  2. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $67,400 14 payments
  3. A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $57,276 16 payments
  4. Open-label Extension Study of Relamorelin for the treatment of diabetic gastroparesis (DG) $10,988 5 payments
  5. 46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $8,403 7 payments
  6. PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) (RPC01-3201) $7,756 1 payment
  7. 46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure $6,394 5 payments
  8. A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $5,573 4 payments
  9. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $3,938 4 payments
  10. 46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $1,719 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record